Insuman Rapid (Insulin Human)

Insulin human mimics the structure of endogenous human insulin and binds to insulin receptors on muscle, fat and liver cells. This activates intracellular signaling pathways that promote glucose uptake, glycogen synthesis, and suppress hepatic glucose production, thereby lowering circulating blood glucose levels.

The dose of Insuman Rapid is individualized. A qualified prescriber determines the amount based on the patient’s blood glucose readings, carbohydrate intake, and overall treatment plan. Dosing may be adjusted frequently, especially around meals or when correcting high glucose levels.

Insulin human is classified as a pregnancy‑category drug that can be used when the benefits outweigh potential risks. It is generally considered safe for pregnant women with diabetes under medical supervision, and it passes into breast milk in small amounts; breastfeeding mothers should consult their healthcare provider.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and necessary import documentation.

Insuman Rapid contains human insulin, whereas many other rapid‑acting products use insulin analogues such as lispro or aspart. Human insulin has a slightly longer onset and duration compared with analogues, but provides comparable glycemic control when dosed appropriately. Choice depends on clinician preference, patient response, and cost considerations.

Insuman Rapid should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vial. Once in use, it may be kept at room temperature (up to 30 °C) for a limited period, typically 28 days, as indicated on the label, and should be discarded after that time.

The product is supplied as a clear solution for subcutaneous injection. It is typically injected into the abdomen, thigh, or upper arm using a sterile needle or an insulin pen compatible with the vial. Injection technique should follow standard aseptic practices and rotate sites to reduce lipodystrophy.

The most serious risks include severe hypoglycemia, which can lead to loss of consciousness or seizures, and allergic reactions ranging from local skin reactions to anaphylaxis. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention for any severe allergic symptoms.

Insuman Rapid is contraindicated in individuals with a known hypersensitivity to insulin human or any excipients in the formulation. It should also be avoided in patients experiencing hypoglycemia unawareness or those with conditions that predispose them to severe low blood glucose without appropriate monitoring.